Gast ::
| Hauptseite > Publikationsdatenbank > Osteopontin Attenuates Secondary Neurodegeneration in the Thalamus after Experimental Stroke > print |
| Hauptseite > Publikationsdatenbank > Osteopontin Attenuates Secondary Neurodegeneration in the Thalamus after Experimental Stroke > print |
| 001 | 863072 | ||
| 005 | 20210130001817.0 | ||
| 024 | 7 | _ | |a 10.1007/s11481-018-9826-1 |2 doi |
| 024 | 7 | _ | |a 1557-1890 |2 ISSN |
| 024 | 7 | _ | |a 1557-1904 |2 ISSN |
| 024 | 7 | _ | |a altmetric:52011798 |2 altmetric |
| 024 | 7 | _ | |a pmid:30488353 |2 pmid |
| 024 | 7 | _ | |a WOS:000468351800011 |2 WOS |
| 024 | 7 | _ | |a 2128/23174 |2 Handle |
| 037 | _ | _ | |a FZJ-2019-03189 |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Ladwig, Anne |0 P:(DE-HGF)0 |b 0 |
| 245 | _ | _ | |a Osteopontin Attenuates Secondary Neurodegeneration in the Thalamus after Experimental Stroke |
| 260 | _ | _ | |a Boston, MA [u.a.] |c 2019 |b Springer |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1559807511_22522 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Cortical cerebral ischemia elicits neuroinflammation as well as secondary neuronal degeneration in remote areas. Locally distinct and specific secondary neurodegeneration affecting thalamic nuclei connected to cortical areas highlights such processes. Osteopontin (OPN) is a cytokine-like glycoprotein that is excreted in high amounts after cerebral ischemia and exerts various immunomodulatory functions. We here examined putative protective effects of OPN in secondary thalamic degeneration. We subjected male Wistar rats to photothrombosis and subsequently injected OPN or placebo intracerebroventricularly. Immunohistochemical and fluorescence staining was used to detect the extent of neuronal degeneration and microglia activation. Ex vivo autoradiography with radiotracers available for human in vivo PET studies, i.e., cis-4-[18F]Fluor-d-Proline (D-cis-[18F]FPro), and [6-3H]thymidine ([3H]thymidine), confirmed degeneration and proliferation, respectively. We found secondary neurodegeneration in the thalamus characterized by microglial activation and neuronal loss. Neuronal loss was restricted to areas of microglial infiltration. Treatment with OPN significantly decreased neurodegeneration, inflammation and microglial proliferation. Microglia displayed morphological signs of activation without expressing markers of M1 or M2 polarization. D-cis-[18F]FPro-uptake mirrored attenuated degeneration in OPN-treated animals. Notably, [3H]thymidine and BrdU-staining revealed increased stem cell proliferation after treatment with OPN. The data suggest that OPN is able to ameliorate secondary neurodegeneration in thalamic nuclei. These effects can be visualized by radiotracers D-cis-[18F]FPro and [3H]thymidine, opening new vistas for translational studies. |
| 536 | _ | _ | |a 573 - Neuroimaging (POF3-573) |0 G:(DE-HGF)POF3-573 |c POF3-573 |f POF III |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef |
| 700 | 1 | _ | |a Rogall, Rebecca |0 P:(DE-HGF)0 |b 1 |
| 700 | 1 | _ | |a Hucklenbroich, Jörg |0 P:(DE-HGF)0 |b 2 |
| 700 | 1 | _ | |a Willuweit, Antje |0 P:(DE-Juel1)144347 |b 3 |
| 700 | 1 | _ | |a Schoeneck, Michael |0 P:(DE-HGF)0 |b 4 |
| 700 | 1 | _ | |a Langen, Karl-Josef |0 P:(DE-Juel1)131777 |b 5 |
| 700 | 1 | _ | |a Fink, Gereon R. |0 P:(DE-Juel1)131720 |b 6 |
| 700 | 1 | _ | |a Adele Rueger, M. |0 P:(DE-HGF)0 |b 7 |
| 700 | 1 | _ | |a Schroeter, Michael |0 0000-0001-8441-4793 |b 8 |e Corresponding author |
| 773 | _ | _ | |a 10.1007/s11481-018-9826-1 |g Vol. 14, no. 2, p. 295 - 311 |0 PERI:(DE-600)2227405-4 |n 2 |p 295 - 311 |t Journal of neuroImmune pharmacology |v 14 |y 2019 |x 1557-1904 |
| 856 | 4 | _ | |u https://juser.fz-juelich.de/record/863072/files/Ladwig2019_Article_OsteopontinAttenuatesSecondary.pdf |y Restricted |
| 856 | 4 | _ | |x pdfa |u https://juser.fz-juelich.de/record/863072/files/Ladwig2019_Article_OsteopontinAttenuatesSecondary.pdf?subformat=pdfa |y Restricted |
| 856 | 4 | _ | |y Published on 2018-11-28. Available in OpenAccess from 2019-11-28. |u https://juser.fz-juelich.de/record/863072/files/Ladwig_2019_Post%20Print_Journal%20of%20Neuroimmune%20Pharmacology_Osteopontin%20attenuates%20secondary%20neurodegeneration%20in%20the%20thalamus%20after%20experimental%20stroke.pdf |
| 856 | 4 | _ | |y Published on 2018-11-28. Available in OpenAccess from 2019-11-28. |x pdfa |u https://juser.fz-juelich.de/record/863072/files/Ladwig_2019_Post%20Print_Journal%20of%20Neuroimmune%20Pharmacology_Osteopontin%20attenuates%20secondary%20neurodegeneration%20in%20the%20thalamus%20after%20experimental%20stroke.pdf?subformat=pdfa |
| 909 | C | O | |o oai:juser.fz-juelich.de:863072 |p openaire |p open_access |p VDB |p driver |p dnbdelivery |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 3 |6 P:(DE-Juel1)144347 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 5 |6 P:(DE-Juel1)131777 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 6 |6 P:(DE-Juel1)131720 |
| 913 | 1 | _ | |a DE-HGF |b Key Technologies |l Decoding the Human Brain |1 G:(DE-HGF)POF3-570 |0 G:(DE-HGF)POF3-573 |2 G:(DE-HGF)POF3-500 |v Neuroimaging |x 0 |4 G:(DE-HGF)POF |3 G:(DE-HGF)POF3 |
| 914 | 1 | _ | |y 2019 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |
| 915 | _ | _ | |a Embargoed OpenAccess |0 StatID:(DE-HGF)0530 |2 StatID |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b J NEUROIMMUNE PHARM : 2017 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |
| 920 | 1 | _ | |0 I:(DE-Juel1)INM-4-20090406 |k INM-4 |l Physik der Medizinischen Bildgebung |x 0 |
| 920 | 1 | _ | |0 I:(DE-Juel1)INM-3-20090406 |k INM-3 |l Kognitive Neurowissenschaften |x 1 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a I:(DE-Juel1)INM-4-20090406 |
| 980 | _ | _ | |a I:(DE-Juel1)INM-3-20090406 |
| 980 | 1 | _ | |a FullTexts |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|